Comparison of automated determination of phosphatidylethanol (PEth) in dried blood spots (DBS) with previous manual processing and testing.

Alcohol biomarker Automated Dried blood spots LC-MS/MS PEth Phosphatidylethanol

Journal

Alcohol (Fayetteville, N.Y.)
ISSN: 1873-6823
Titre abrégé: Alcohol
Pays: United States
ID NLM: 8502311

Informations de publication

Date de publication:
02 2022
Historique:
received: 31 03 2021
revised: 02 11 2021
accepted: 03 11 2021
pubmed: 13 11 2021
medline: 25 3 2022
entrez: 12 11 2021
Statut: ppublish

Résumé

Phosphatidylethanol (PEth) is a sensitive and specific biomarker of alcohol consumption in the prior 2-3 weeks. Standard, manual PEth testing using dried blood spots (DBS) is a multi-step time-consuming process. A novel, automated processing and testing method has been developed to decrease DBS processing and testing time. We conducted automated testing, using regioisomerically pure PEth reference material, on randomly selected DBS, which had previously been tested via manual methods and then stored for 3-6 years at -80 °C, to compare the results (PEth 16:0/18:1 homologue). We chose samples for re-testing using categories found in the literature as follows: 1) PEth <20 ng/mL; 2) PEth 20-200 ng/mL; 3) PEth >200-1000 ng/mL; 4) PEth >1000 ng/mL. We calculated agreement between the categories using the weighted kappa statistic (n = 49 DBS). We quantified agreement between continuous measures using the intraclass correlation coefficient (ICC), and further described the relationship between variables using Spearman correlation. The median PEth result was 155 ng/mL (interquartile range [IQR]: 1-1312 ng/mL) via automated methods and 98.8 ng/mL (IQR: 10.2-625.0 ng/mL) via manual methods. The weighted kappa comparing the automated to manual PEth results was 0.76 [95% Confidence Interval (CI): 0.66-0.86]. The ICC was 0.69 (95% CI: 0.54-0.79), and the Spearman correlation was 0.98 (95% CI: 0.95-0.99). While the new methods yielded somewhat higher PEth values, we found good to excellent agreement between clinically relevant PEth categories. Automated DBS processing and testing using new reference standards are promising methods for PEth testing.

Identifiants

pubmed: 34767948
pii: S0741-8329(21)00136-1
doi: 10.1016/j.alcohol.2021.11.001
pmc: PMC9829025
mid: NIHMS1855486
pii:
doi:

Substances chimiques

Biomarkers 0
Glycerophospholipids 0
phosphatidylethanol 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-54

Subventions

Organisme : NIAAA NIH HHS
ID : K24 AA022586
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020776
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020779
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr. Marc Luginbühl and Dr. Stefan Gaugler are employees of the DBS research laboratory at CAMAG (Muttenz, Switzerland), and did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors for this work. CAMAG donated the materials needed to do the automated testing.

Références

Alcohol Clin Exp Res. 2015 Nov;39(11):2060-72
pubmed: 26344403
Mass Spectrom Rev. 2016 May-Jun;35(3):361-438
pubmed: 25252132
J Anal Toxicol. 2019 Jul 24;43(6):489-496
pubmed: 31062845
Lancet HIV. 2019 Aug;6(8):e509-e517
pubmed: 31109915
AIDS Care. 2017 Nov;29(11):1442-1447
pubmed: 28278568
Alcohol Clin Exp Res. 2018 Jan;42(1):128-134
pubmed: 29080351
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
J Forensic Sci. 2018 Nov;63(6):1634-1640
pubmed: 30005144
Anal Bioanal Chem. 2016 Jan;408(3):825-38
pubmed: 26597914
AIDS Behav. 2019 Jun;23(6):1656-1667
pubmed: 30560484
J Anal Toxicol. 2021 Feb 6;45(1):76-83
pubmed: 32248226
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):492-501
pubmed: 29303844
PLoS One. 2014 Dec 01;9(12):e113152
pubmed: 25436894
Lakartidningen. 2013 Sep 25-Oct 8;110(39-40):1747-8
pubmed: 24245431
Alcohol Clin Exp Res. 2015 Nov;39(11):2200-8
pubmed: 26503066
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):135-143
pubmed: 29112041

Auteurs

Robin Fatch (R)

Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, CA, United States.

Marc Luginbühl (M)

CAMAG DBS Laboratory, Muttenz, Switzerland.

Debbie M Cheng (DM)

Boston University School of Public Health, Boston, MA, United States.

Stefan Gaugler (S)

CAMAG DBS Laboratory, Muttenz, Switzerland.

Nneka I Emenyonu (NI)

Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, CA, United States.

Christine Ngabirano (C)

Mbarara University of Science and Technology, Mbarara, Uganda.

Julian Adong (J)

Mbarara University of Science and Technology, Mbarara, Uganda.

Winnie R Muyindike (WR)

Mbarara University of Science and Technology, Mbarara, Uganda.

Jeffrey H Samet (JH)

Boston University School of Public Health, Boston, MA, United States; Boston University School of Medicine; Boston Medical Center, Boston, MA, United States.

Kendall Bryant (K)

National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States.

Judith A Hahn (JA)

Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, CA, United States; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States. Electronic address: judy.hahn@ucsf.edu.

Articles similaires

C-Reactive Protein Humans Biomarkers Inflammation
Humans Retrospective Studies Male Critical Illness Female
Humans Male Female Intensive Care Units COVID-19

Classifications MeSH